First-order effects

• Myhrvold's fund gains its most valuable validation yet — blue-chip tech companies treating patents as an asset class worth paying for — while Kedrosky's rebuttal gives skeptics a citable counterargument in the same news cycle.
• Large technology firms weighing patent purchases now face a public argument that the 'value' being discovered is transfer pricing among incumbents, not new invention.

Second-order effects

• If incumbents keep buying into the patent market, smaller software companies inherit higher licensing and litigation exposure, since aggregated portfolios get enforced against the whole field, not just rival giants.
• Rivals and critics of the aggregation model gain a rhetorical opening: every mainstream airing of Myhrvold's case invites scrutiny of whether his funds' returns come from innovation or from leverage.

Third-order effects

• The episode marks patents drifting from an incentive for inventors toward a tradable financial instrument managed by intermediaries — a shift that, if it holds, forces policymakers to choose between protecting portfolio owners and lowering barriers for operating companies.
• A durable fault line opens in Silicon Valley between firms that can afford defensive patent war chests and those priced out of the market entirely.